Evidence map›Paper›PMID 37821462›Full record

ArticleCell death & disease2023

USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation.

Deng Yong Zhang, Yan Zhu, Qiong Wu, Shuoshuo Ma, Yang Ma, Zheng Chao Shen, Zhonglin Wang, Wanliang Sun, Yong Chun Zhou, Dongdong Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. SRY mediates male-specific susceptibility to acute liver injury.Cell communication and signaling : CCS · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Prospects for PARG inhibitors in cancer therapy.Journal of molecular cell biology · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Deng Yong Zhang *Department of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.ORCID 0000-0003-4408-3357
Yan Zhu *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Qiong Wu *Department of pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.ORCID 0009-0007-7832-1460
Shuoshuo MaDepartment of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.ORCID 0000-0003-3571-6546
Yang MaDepartment of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.ORCID 0000-0002-1421-7038
Zheng Chao ShenDepartment of General Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu, 241001, Anhui, China.
Zhonglin WangSocial Science Research Institute, Duke University, Durham, NC, 27708, USA.
Wanliang SunDepartment of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.ORCID 0000-0002-8207-5481
Yong Chun ZhouDepartment of Radiotherapy, The First Affiliated Hospital of Bengbu Medical College, Anhui, China.
Dongdong WangDepartment of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.
Shuo ZhouDepartment of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.
Zhong LiuDepartment of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China.ORCID 0009-0007-2556-6085
Lawrence N KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. lkwong@mdanderson.org.ORCID 0000-0001-8370-1432
Zheng LuDepartment of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, Anhui, China. luzhengdr@bbmc.edu.cn.ORCID 0000-0002-9090-0875
First Affiliated Hospital of Bengbu Medical College · CNThe University of Texas MD Anderson Cancer Center · USAnhui Medical University · CNBengbu Medical College · CNFirst Affiliated Hospital of Wannan Medical College · CNSocial Science Research Council · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite its involvement in various cancers, the function of the deubiquitinase USP1 (ubiquitin-specific protease 1) is unexplored in cholangiocarcinoma (CCA). In this study, we provide evidence that USP1 promotes CCA progression through the stabilization of Poly (ADP-ribose) polymerase 1 (PARP1), consistent with the observation that both USP1 and PARP1 are upregulated in human CCA. Proteomics and ubiquitylome analysis of USP1-overexpressing CCA cells nominated PARP1 as a top USP1 substrate. Indeed, their direct interaction was validated by a series of immunofluorescence, co-immunoprecipitation (CO-IP), and GST pull-down assays, and their interaction regions were identified using deletion mutants. Mechanistically, USP1 removes the ubiquitin chain at K197 of PARP1 to prevent its proteasomal degradation, with the consequent PARP1 stabilization being necessary and sufficient to promote the growth and metastasis of CCA in vitro and in vivo. Additionally, we identified the acetyltransferase GCN5 as acetylating USP1 at K130, enhancing the affinity between USP1 and PARP1 and further increasing PARP1 protein stabilization. Finally, both USP1 and PARP1 are significantly associated with poor survival in CCA patients. These findings describe PARP1 as a novel deubiquitination target of USP1 and a potential therapeutic target for CCA.

Indexed as

CholangiocarcinomaUbiquitin-Specific ProteasesHumansPoly (ADP-Ribose) Polymerase-1PARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Ubiquitin-Specific ProteasesUSP1 protein, human

Identifiers

PMID37821462
PMCPMC10567853
OpenAlexW4387539357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.